Kate Therapeutics

This June 20th for World FSHD Day, the team at Kate Therapeutics is proud to join the voices of patients, caregivers, and loved ones as we move together towards a safe and effective treatment. Join the Orange Slice Selfie Challenge: https://lnkd.in/gNRy8hCZ #OrangeSliceSelfie #WorldFSHDDay

Our CSO Sharif Tabebordbar, Ph.D., will be presenting at the 31st Annual International Research Congress on FSHD hosted by the FSHD Society in Denver, on June 13th at 12pm. This prestigious event brings together leading researchers and experts from around the world to discuss advancements in the understanding and treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).   Sharif's presentation is focused on our work developing a potent one-time muscle directed gene therapy candidate for the treatment of FSHD through high-throughput AAV capsid and cargo engineering.   You can find out more here: https://lnkd.in/gcVmherB   #FSHD #Research #GeneticTherapies #KateTherapeutics #Innovation #Healthcare #SharifTabebordbar #FSHDSociety

We’re #hiring. Know anyone who might be interested?

Big thank you to our volunteers for donating their time to speak to high school students interested in careers in STEM.

We are excited to share our latest research in Duchenne Muscular Dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD) at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting.   Keynote lecture: Chief Scientific Officer Sharif Tabebordbar, Ph.D. ASGCT 2024 Outstanding Investigator Award Winner   Friday, May 10, 2024, at 11:40 AM ET.   🔗 To learn more see our press release here: https://bit.ly/44GROuv   #KateTherapeutics #GeneTherapy #DuchenneMuscularDystrophy #DMD #ASGCT2024 #HealthcareInnovation #Biotech #MedicalResearch

We are excited to announce that Kate Therapeutics’ Chief Scientific Officer and Co-Founder Sharif Tabebordbar, was recently named a recipient of the prestigious American Society of Gene & Cell Therapy “Outstanding New Investigator Award.”   This recognition underscores Sharif's exceptional early career contributions to the field of AAV gene therapy and the potential of Kate’s muscle- and heart-directed medicines to provide safe and effective treatments for patients. Congratulations, Sharif! https://lnkd.in/gDaeW3uf #ASGCT #YoungInvestigatorAward #GeneticMedicine #GeneTherapy #KateTherapeutics

Sharif Tabebordbar., Kate’s co-founder and Chief Scientific Officer will be presenting at the Muscular Dystrophy Association Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.   Sharif’s talk is entitled “Directed Evolution of Novel MyoAAV Capsid Variants Enabling Effective Systemic Muscle Transduction While De-Targeting The Liver in Non-Human Primates.” It will be held within the session “Disease Mechanism & Therapeutic Strategies” in the Florida Room 1-3, between 2-4pm ET.   We hope to see you there!   Learn More: https://lnkd.in/g9NtQfY   #genetherapy #myoAAV  

Here at Kate dedication to OUR TEAM is one of our daily Core Values. Today, for employee Appreciation Day, we get to thank our employees once again for being a valuable member of our team. #employeeappreciationday

At Kate Therapeutics we are focused on developing AAV-based gene therapies to treat genetically defined muscle and heart diseases. Rare Disease Day is a reminder of our commitment to advancing important medicines to patients with limited treatment options. Learn More: https://lnkd.in/gk6hbAF #genetherapy #rarediseaseday2024

We're #hiring a new Research Associate/ Senior Research Associate – Drug Discovery, Gene Therapy in San Diego Metropolitan Area. Apply today or share this post with your network.